Who are Fludrocortisone Acetate Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludrocortisone/ Fludrocortisone acetate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludrocortisone-acetate-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fludrocortisone Acetate Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludrocortisone Acetate Tablets (Fludrocortisone Acetate Tablets) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineralocorticoid receptor agonist. Area: Endocrinology / Cardiovascular.

phase 3 Mineralocorticoid receptor agonist Mineralocorticoid receptor (MR) Endocrinology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Fludrocortisone Acetate Tablets (Fludrocortisone Acetate Tablets) — Tehran Heart Center. Fludrocortisone acetate is a synthetic mineralocorticoid that enhances sodium reabsorption and potassium excretion in the distal renal tubules, thereby increasing blood volume and blood pressure.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fludrocortisone Acetate Tablets TARGET	Fludrocortisone Acetate Tablets	Tehran Heart Center	phase 3	Mineralocorticoid receptor agonist	Mineralocorticoid receptor (MR)
Fludrocortisone/ Fludrocortisone acetate	Fludrocortisone/ Fludrocortisone acetate	Merck Sharp & Dohme LLC	marketed	Mineralocorticoid receptor agonist; corticosteroid	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineralocorticoid receptor agonist class)

Tehran Heart Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludrocortisone Acetate Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/fludrocortisone-acetate-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing